CLASP IID: The PASCAL system is a safe and beneficial therapy for severe degenerative mitral regurgitation
Key Points: The MitraClip system has been established as a robust platform…
PROTECTED TAVR: No Overall Stroke Reduction With Embolic Protection Devices in TAVR, But Fewer Disabling Strokes
Key Points: Stroke is a feared complication of TAVR. However, the potential…
Radial cath associated with fewer deaths and bleeding: RTC study
Key Points Transradial access has emerged as the preferred initial access method…
Full-dose anticoagulation prevents thrombotic events in COVID patients: COVID-PACT
Key Points Given the increased thrombotic risk in COVID patients, there has…
Coronary Artery Plaque Activity Predicts Recurrent Cardiac Events: results from the PRE-18FFR Trial
Key Points Understanding the future risk of myocardial infarction and death for…
When and How Much Should We lower LDL and Systolic Blood Pressure in Our Patients? Artificial Intelligence and Causal Effects May Provide Answers
Key Points: • Current risk estimating algorithms exclude causal effects and therefore…
It’s Time to Randomize: Smartphone-Based Screening for Atrial Fibrillation – The Siteless, Digital, Randomized eBRAVE-AF Trial
Key Points Wearable technologies based on photoplethysmographic measurements of irregular pulses can…
Artificial Intelligence can improve detection of severe aortic stenosis from echocardiograms: AI-ENHANCED AS shows.
Key Points Aortic stenosis, despite being life-threatening, is often underdiagnosed. It is…
Uncoupling Hemostasis from Thrombosis: Adding Oral FXIa Inhibitor Asundexian to Antiplatelet Therapy After Acute Non-Cardioembolic Stroke – PACIFIC-STROKE
Key Points Selective XIa inhibitor Asundexian may innovate the field of oral…
Uncoupling Hemostasis from Thrombosis: Adding Oral FXIa Inhibitor Asundexian to DAPT After Acute Myocardial Infarction – PACIFIC-AMI.
Key Points Selective XIa inhibitor Asundexian may innovate the field of oral…
Acetazolamide results in improved decongestion, faster: results from ADVOR
Key Points: Residual decongestion after a hospitalization for acute decompensated heart failure…
More Evidence For the Newest Guideline Directed Medical Therapy Pillar – Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (The DELIVER Trial)
Key Points: The use of sodium-glucose cotransporter-2 inhibitor (SGLT2i) in heart failure…
Routine PCI confers no added benefit in severe left ventricular dysfunction: REVIVED
Key Points REVIVED is the first large scale clinical trial to assess…
Sacubitril/Valsartan has no significant effect on cognition: PERSPECTIVE
Key Points There has been a theoretical concern of potential increased amyloid…
Less Structural Valve Deterioration at 5 years with TAVR: Insights from CoreValve/SURTAVI Trials
Key Points: As transcatheter aortic valve replacement (TAVR) has experienced expanded indications…
CLASP-TR demonstrates significant improvement in tricuspid regurgitation up to one year after procedure.
Key Points Tricuspid regurgitation is a debilitating valve disorder characterized by shortness…
Uncoupling Hemostasis from Thrombosis: A Promising Comparison of Oral FXIa Inhibitor Asundexian Versus Apixaban in Patients with Atrial Fibrillation – But More Data Are Needed.
Key Points Selective XIa inhibitor Asundexian may innovate the field of oral…
Alirocumab initiation after MI associated with lower plasma atheroma volume: PACMAN-AMI
Key Points PCSK-9 inhibitors have emerged as a viable treatment option patients…
Mavacamten improves LVOT gradients in patients with HCM: EXPLORER-LTE
Key Points: In the EXPLORER-LTE study, patients with severely symptomatic obstructive HCM…
Vupanorsen shown to effectively decrease non-HDL cholesterol in patients already on statins: TRANSLATE-TIMI 70
Key Points: A need for various lipid-lowering agents to combat high cholesterol…